Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Fig. 4

AGI-134 treatment of primary tumors produces an abscopal effect protecting mice from contralateral tumor development. a Schematic of abscopal B16-F10 melanoma model in anti-Gal-expressing α1,3GT−/− mice. To monitor the abscopal effect of AGI-134, primary B16-F10 lesions were treated once by intratumoral injection of PBS or 1 mg AGI-134 and the development of contralateral lesions monitored. The percentages of mice without visible/palpable contralateral tumors are plotted in the graphs. The solid arrows indicate the day of AGI-134 or mock treatment (Day 4–6). b The pooled data from four independent experiments where the abscopal effect in B16-F10 tumors was monitored over 25 days are summarized. c B16-F10 tumors in immunized (anti-Gal positive) or non-immunized (anti-Gal negative) α1,3GT−/− mice were treated i.t. with vehicle, or 1 mg AGI-134. d Representative data from two experiments where the abscopal effect of AGI-134 in B16-F10 tumors was monitored over 60–90 days is shown. Statistical differences between treatment groups in each plot were analyzed by Mantel–Cox test (**p < 0.005; ***p < 0.0005)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us